Beta Bionics (NASDAQ:BBNX) Trading Down 4.3% on Insider Selling

Beta Bionics, Inc. (NASDAQ:BBNX)’s share price fell 4.3% during trading on Thursday following insider selling activity. The stock traded as low as $21.37 and last traded at $21.2260. 990,815 shares were traded during mid-day trading, a decline of 16% from the average session volume of 1,178,910 shares. The stock had previously closed at $22.18.

Specifically, insider Mike Mensinger sold 2,650 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider directly owned 177,390 shares of the company’s stock, valued at approximately $3,902,580. This trade represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 30,779 shares of Beta Bionics stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the sale, the insider owned 56,479 shares in the company, valued at $1,136,922.27. This trade represents a 35.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BBNX. Truist Financial restated a “buy” rating and issued a $23.00 price objective (up from $22.00) on shares of Beta Bionics in a research note on Tuesday. Robert W. Baird lifted their target price on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday. Bank of America boosted their price target on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday. UBS Group restated a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research report on Tuesday. Finally, William Blair started coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating for the company. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.90.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

Beta Bionics Trading Up 2.1%

The firm has a fifty day moving average of $17.66 and a two-hundred day moving average of $14.05. The company has a market cap of $984.83 million, a PE ratio of -13.27 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. Sell-side analysts expect that Beta Bionics, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Beta Bionics

Several hedge funds and other institutional investors have recently modified their holdings of BBNX. BlackRock Inc. bought a new position in Beta Bionics in the 2nd quarter worth approximately $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics in the 4th quarter valued at approximately $40,437,000. Eversept Partners LP raised its holdings in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after acquiring an additional 736,576 shares during the period. 12 West Capital Management LP bought a new stake in Beta Bionics during the 4th quarter valued at $17,520,000. Finally, Bruce & Co. Inc. purchased a new stake in shares of Beta Bionics during the first quarter worth $5,518,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.